ID

17784

Descrizione

Glutamine in Treating Neuropathy Caused by Vincristine in Young Patients With Lymphoma, Leukemia, or Solid Tumors; ODM derived from: https://clinicaltrials.gov/show/NCT00365768

collegamento

https://clinicaltrials.gov/show/NCT00365768

Keywords

  1. 02/10/16 02/10/16 -
  2. 03/10/16 03/10/16 -
Caricato su

3 ottobre 2016

DOI

Per favore, per richiedere un accesso.

Licenza

Creative Commons BY 4.0

Commenti del modello :

Puoi commentare il modello dati qui. Tramite i fumetti nei gruppi di articoli e articoli è possibile aggiungere commenti a quelli in modo specifico.

Commenti del gruppo di articoli per :

Commenti dell'articolo per :

Per scaricare i modelli di dati devi essere registrato. Per favore accesso o registrati GRATIS.

Eligibility Kidney Cancer NCT00365768

Eligibility Kidney Cancer NCT00365768

Inclusion Criteria
Descrizione

Inclusion Criteria

Alias
UMLS CUI
C1512693
patients between the age of 5 and 21 years old.
Descrizione

Age

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0001779
patients who demonstrate the ability to complete the assessment instruments at baseline.
Descrizione

Assessment Complete Ability

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C1516048
UMLS CUI [1,2]
C0205197
UMLS CUI [1,3]
C0085732
patients who are diagnosed with leukemia or solid tumors and are expected to receive a cumulative dose of > or = to 6mg/m2 of vincristine, or > 6mg if individual vincristine doses are capped at 2mg according to primary cancer treatment protocol, over a 30-week period.
Descrizione

leukemia | Solid tumour | Vincristine Cumulative Dose Expected | Vincristine individual dose

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0023418
UMLS CUI [2]
C0280100
UMLS CUI [3,1]
C0042679
UMLS CUI [3,2]
C2986497
UMLS CUI [3,3]
C1517001
UMLS CUI [4,1]
C0042679
UMLS CUI [4,2]
C0677260
Exclusion Criteria
Descrizione

Exclusion Criteria

Alias
UMLS CUI
C0680251
patients with primary cns tumors other than medulloblastoma or patients with cns metastasis.
Descrizione

Primary malignant neoplasm of central nervous system | Medulloblastoma | CNS metastases

Tipo di dati

boolean

Alias
UMLS CUI [1]
C1455806
UMLS CUI [2]
C0025149
UMLS CUI [3]
C0686377
patients with recurrent disease.
Descrizione

Recurrent disease

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0277556
patients with grade ii, iii or iv neurological status by the nci ctc (ver. 3.0) on clinical exam.
Descrizione

Neurological status | CTCAE grade finding | examination; clinical

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0746866
UMLS CUI [2]
C3887242
UMLS CUI [3]
C1456356
patients who have already received > 8mg/m2 of vincristine, or > 8mg if individual vincristine doses are capped at 2mg according to primary cancer treatment protocol, during their course of therapy at time of consent.
Descrizione

Vincristine Dose | Vincristine individual dose

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0042679
UMLS CUI [1,2]
C0178602
UMLS CUI [2,1]
C0042679
UMLS CUI [2,2]
C0677260
patients with hepatic encephalopathy or hyperammonemia.
Descrizione

Hepatic Encephalopathy | Hyperammonemia

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0019151
UMLS CUI [2]
C0220994
patients with a focally abnormal neurologic exam.
Descrizione

Neurological examination abnormal Focal

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C1112537
UMLS CUI [1,2]
C0205234

Similar models

Eligibility Kidney Cancer NCT00365768

Name
genere
Description | Question | Decode (Coded Value)
Tipo di dati
Alias
Item Group
C1512693 (UMLS CUI)
Age
Item
patients between the age of 5 and 21 years old.
boolean
C0001779 (UMLS CUI [1])
Assessment Complete Ability
Item
patients who demonstrate the ability to complete the assessment instruments at baseline.
boolean
C1516048 (UMLS CUI [1,1])
C0205197 (UMLS CUI [1,2])
C0085732 (UMLS CUI [1,3])
leukemia | Solid tumour | Vincristine Cumulative Dose Expected | Vincristine individual dose
Item
patients who are diagnosed with leukemia or solid tumors and are expected to receive a cumulative dose of > or = to 6mg/m2 of vincristine, or > 6mg if individual vincristine doses are capped at 2mg according to primary cancer treatment protocol, over a 30-week period.
boolean
C0023418 (UMLS CUI [1])
C0280100 (UMLS CUI [2])
C0042679 (UMLS CUI [3,1])
C2986497 (UMLS CUI [3,2])
C1517001 (UMLS CUI [3,3])
C0042679 (UMLS CUI [4,1])
C0677260 (UMLS CUI [4,2])
Item Group
C0680251 (UMLS CUI)
Primary malignant neoplasm of central nervous system | Medulloblastoma | CNS metastases
Item
patients with primary cns tumors other than medulloblastoma or patients with cns metastasis.
boolean
C1455806 (UMLS CUI [1])
C0025149 (UMLS CUI [2])
C0686377 (UMLS CUI [3])
Recurrent disease
Item
patients with recurrent disease.
boolean
C0277556 (UMLS CUI [1])
Neurological status | CTCAE grade finding | examination; clinical
Item
patients with grade ii, iii or iv neurological status by the nci ctc (ver. 3.0) on clinical exam.
boolean
C0746866 (UMLS CUI [1])
C3887242 (UMLS CUI [2])
C1456356 (UMLS CUI [3])
Vincristine Dose | Vincristine individual dose
Item
patients who have already received > 8mg/m2 of vincristine, or > 8mg if individual vincristine doses are capped at 2mg according to primary cancer treatment protocol, during their course of therapy at time of consent.
boolean
C0042679 (UMLS CUI [1,1])
C0178602 (UMLS CUI [1,2])
C0042679 (UMLS CUI [2,1])
C0677260 (UMLS CUI [2,2])
Hepatic Encephalopathy | Hyperammonemia
Item
patients with hepatic encephalopathy or hyperammonemia.
boolean
C0019151 (UMLS CUI [1])
C0220994 (UMLS CUI [2])
Neurological examination abnormal Focal
Item
patients with a focally abnormal neurologic exam.
boolean
C1112537 (UMLS CUI [1,1])
C0205234 (UMLS CUI [1,2])

Si prega di utilizzare questo modulo per feedback, domande e suggerimenti per miglioramenti.

I campi contrassegnati da * sono obbligatori.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial